In Brief: OncoMembrane's Ferriseltz
Executive Summary
OncoMembrane's Ferriseltz: Positive MRI contrast agent for gastrointestinal use receives "approvable" letter from FDA Nov. 15, reports Seattle-based OncoMembrane, a subsidiary of Otsuka Pharmaceuticals. The oral ferric ammonium citrate product will be promoted on safety, taste and low cost, company says. Marketing approval is pending completion of stability study. The Ferriseltz NDA was filed Jan. 15...